Money-back guarantees fail to boost cost-effectiveness of PCSK9 inhibitors

Outcomes-based pricing agreements would do little to help the poor cost-effectiveness of PCSK9 inhibitors. The event rates in preventive medicine are simply too low and medication costs too high for such a compromise to make a difference, a group from University of California, San Francisco reported in the Annals of Internal Medicine.